The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?

The Cooper Companies is expected to report fiscal Q3 2026 sales of $1.1 billion, up 3.6% year over year, and adjusted EPS of $1.11, up 0.9%, after the Sept. 9 market close. CooperVision demand and improving CooperSurgical fertility trends should support results, while Asia-Pacific weakness, FX, tariffs, freight costs and lower production could pressure gross margins. Management maintained full-year adjusted EPS guidance of $4.58-$4.66, but COO carries a Zacks Rank #4 (Sell) and its Earnings ESP is 0.00%; shares are down 17.4% year to date versus a 7.3% industry gain.

Analysis

COO’s setup is less about whether it clears a low single-digit earnings bar and more about the quality of growth needed to re-rate a stock that has materially lagged healthcare peers. The key sensitivity is whether premium daily lenses and myopia-control products can offset Asia-Pacific weakness without incremental discounting; evidence of sustained mix improvement would support gross-margin recovery and a 6-12 month multiple expansion. Conversely, growth supported by temporary fertility-equipment demand or distributor inventory would have limited valuation value and likely prompt a sell-the-news reaction.

The most consequential near-term disclosure is the outlook for Asia-Pacific and online-channel exposure. Continued regional weakness creates a competitive opening for spectacle-based myopia-control providers and lower-priced local lens alternatives, while tariff, freight and FX pressure may expose how much of recent cost savings is structural versus merely offsetting inflation. A modest beat paired with unchanged guidance is unlikely to change the narrative; an organic-growth acceleration or higher full-year earnings guide is the required catalyst over the next 1-3 months.

Contrarianly, COO’s weak relative performance may have already discounted a soft quarter, making downside asymmetric only if management cuts guidance or signals that premium-lens adoption is slowing outside Asia. The cleaner relative expression is COO versus WST or GMED: those names have stronger current estimate momentum, so a post-print COO rebound should be treated as tactical unless management demonstrates durable operating leverage and fertility consumables growth rather than capital-equipment volatility.

Key Decisions for Investors

• Maintain no directional pre-earnings position in COO absent options-implied move and positioning data; the available evidence does not establish a differentiated revenue or EPS edge.
• For a tactical bearish view, consider a small COO / long GMED pair initiated only if COO rallies 5%+ into results without upward estimate revisions; target 8-12% relative downside over 1-3 months. Exit if COO raises full-year EPS guidance or reports broad-based organic growth acceleration outside Asia-Pacific.
• Post-results, go long COO only if management lifts guidance and demonstrates that premium daily-lens mix plus fertility consumables—not distributor restocking or equipment sales—are driving growth. Target a 10-15% recovery over 3-6 months; invalidate on another Asia-Pacific deterioration or gross-margin guide-down.
• Monitor COO’s commentary on tariffs, FX and freight versus WST’s margin outlook. Broad medical-device input-cost pressure would favor avoiding margin-sensitive mid-cap healthcare exposure rather than treating COO’s cost actions as company-specific alpha.